Startup profile · funding coverage
Biolevate funding, valuation and investors
Life-sciences automation company that raised a €30 million Series A and opened a Boston office.
Keep track of Biolevate
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
€30M · September 22, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Paris, France
Investors in latest funding
Lead: RAISE France , Orange Ventures
Other: MSD Global Health Innovation Fund , EQT Ventures
Overview
Biolevate builds knowledge-driven automation software for life-sciences operations. On September 22, 2026 it announced a €30 million Series A co-led by RAISE France and Orange Ventures, with MSD Global Health Innovation Fund, Station F and EQT Ventures participating.
Why Biolevate is interesting
Strong life-sciences AI theme, company-reported 20x ARR growth, and a material Series A from recognizable investors.
Key facts
- Sep 22, 2026: €30M Series A
- Company said ARR increased 20x over the prior 12 months
Funding history (newest first)
Series A
2026-09-22 €30M- RAISE France (lead)
- Orange Ventures (lead)
- MSD Global Health Innovation Fund (participant)
- EQT Ventures (participant)
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Biolevate
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.